Annual report pursuant to Section 13 and 15(d)

Summary of Significant Accounting Policies (Tables)

v3.6.0.2
Summary of Significant Accounting Policies (Tables)
12 Months Ended
Dec. 31, 2016
Summary of Significant Accounting Policies  
Schedule operating expenses for comparative periods as previously reported and as presented after the reclassifications

The operating expenses for comparative periods as previously reported and as presented after the reclassifications are as follows (in thousands):

 

 

 

Six months ended
December 31, 2015

 

Year ended
June 30, 2015

 

Year ended
June 30, 2014

 

 

 

As previously
reported

 

After
reclassification

 

As previously
reported

 

After
reclassification

 

As previously
reported

 

After
reclassification

 

Research and development

 

$

24,244 

 

$

25,472 

 

$

23,278 

 

$

24,137 

 

$

9,746 

 

$

9,575 

 

General and administrative

 

11,145 

 

9,917 

 

11,234 

 

10,375 

 

2,600 

 

2,771 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total operating expenses

 

$

35,389 

 

$

35,389 

 

$

34,512 

 

$

34,512 

 

$

12,346 

 

$

12,346 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Schedule of the reconciliation of cash, cash equivalents, and restricted cash

The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the balance sheet that sum to the total of the same such amounts shown in the statement of cash flows (in thousands).

 

 

 

December 31,
2016

 

December 31,
2015

 

June 30,
2015

 

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

158,779 

 

$

194,263 

 

$

229,046 

 

Restricted cash

 

4,017 

 

4,508 

 

 

 

 

 

 

 

 

 

 

Total cash, cash equivalents, and restricted cash shown in the statement of cash flows

 

$

162,796 

 

$

198,771 

 

$

229,046 

 

 

 

 

 

 

 

 

 

 

 

 

 

Schedule of estimated useful lives of property, plant and equipment

Computer equipment

 

3 to 5 years

 

Laboratory equipment

 

5 years

 

Office equipment

 

5 years

 

Leasehold improvements

 

the expected duration of the lease

 

 

Schedule of numerator and denominator in the basic and diluted loss per share computation

The following table reconciles the numerator and denominator in the basic and diluted loss per share computation (in thousands):

 

 

 

Year ended
December 31,
2016

 

Six months
ended
December 31,
2015

 

Year ended
June 30,
2015

 

Year ended
June 30,
2014

 

Numerator for basic and diluted loss per share

 

 

 

 

 

 

 

 

 

Net loss

 

$

(71,579

)

$

(23,000

)

$

(22,058

)

$

(11,601

)

Deemed dividend on convertible preferred shares

 

 

 

(14,735

)

 

 

 

 

 

 

 

 

 

 

 

Net loss attributable to ordinary shareholders

 

$

(71,579

)

$

(23,000

)

$

(36,793

)

$

(11,601

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Denominator for basic and diluted loss per share

 

 

 

 

 

 

 

 

 

Weighted average number of shares used to calculate basic and diluted loss per share

 

424,713,997

 

424,711,900

 

214,704,593

 

148,335,529

 

 

Schedule of potentially dilutive equity instruments excluded from the diluted loss per share calculation

 

 

Year ended
December 31,
2016

 

Six months
ended
December 31,
2015

 

Year ended
June 30,
2015

 

Year ended
June 30,
2014

 

 

 

 

 

 

 

 

 

 

 

Weighted average number of share options(1)

 

45,882,791 

 

31,203,477 

 

31,473,477 

 

10,057,700 

 

Weighted average number of Preferred Shares(2)

 

 

 

122,848,381 

 

 

 

 

(1)

The Company granted a total of 15,543,040 options from January 1, 2017 through to March 8, 2017.

 

(2)

Adaptimmune Limited issued 1,758,418 Series A Preferred Shares in September 2014.  In April 2015, as part of the Company reorganization, the Series A Preferred Shares of Adaptimmune Limited were exchanged for Series A Preferred Shares of Adaptimmune Therapeutics Limited on a one-for-100 basis. The Series A Preferred Shares were converted into ordinary shares at a rate of 1:1 immediately prior to the Company’s initial public offering on NASDAQ in May 2015.